今年以来，港股及A股市场走势向好，牛市预期进一步升温。医疗器械板块亦迎来积极信号，此前中信建投研报指出，随着集采政 策优化、设备招标数据改善及渠道库存去化，多个细分领域正陆续迎来业绩拐点。与此同时，国产医疗器械出海趋势明确，具备 全球竞争力的公司正迎来估值重塑机遇。 在此背景下，笔者留意到微泰医疗-B（02235.HK）发布了一份颇为亮眼的年度业绩预告。公司过去一年实现收入大幅增长，并成 功扭亏为盈。公告将增长归因于CGM收入强劲增长、海外市场显著突破及经营效率提升。 可以说这份预告不仅验证了微泰医疗的高增长，更标志着其已迈入利润释放新周期，亦符合当前市场聚焦"出海+业绩"的方向，不 妨就此来看公司的机会所在。 01 长坡厚雪，CGM赛道CGM的消费化浪潮与国产出海机遇 医药投资中，往往具备"长赛道、高壁垒、强成长"特征的细分领域更具吸引力，糖尿病管理无疑是其中的典型代表。其一方面有 庞大的存量患者基础，另一方面又有持续的技术迭代红利，放在任何市场的医药投资框架里，这都是值得长期跟踪的黄金赛道。 从行业基本面来看，全球糖尿病患者基数大且仍在持续扩大。IDF数据显示，2024年全球糖尿病患者已突破5.89亿，中 ...

Investment Rating - The report maintains a "Buy" rating for the medical services industry, suggesting a positive outlook for investment opportunities in this sector [10][64]. Core Insights - The medical services sector has shown resilience, with a recent increase in the sector's PE ratio to 34.43X and PB ratio to 3.49X, indicating a positive trend in valuation metrics [4][29]. - The approval of internet medical first diagnosis trials in Beijing marks a significant regulatory breakthrough, potentially accelerating the online medical service process and providing new market opportunities for private medical institutions [5][62][63]. - The report highlights the importance of digital regulation and standardization in enhancing service capabilities for private medical institutions, particularly in consumer healthcare sectors like pediatrics and dermatology [5][62]. Summary by Sections Industry Performance - The pharmaceutical and biological sector increased by 0.14%, ranking 15th among 31 primary industries, outperforming the Shanghai Composite Index by 1.47 percentage points [2][12]. - The medical services sub-sector reported a 1.31% increase, closing at 6827.17 points, with a year-to-date performance of 41.41% [24][27]. Company Performance - Top-performing companies in the medical services sector include Meidisi (+18.0%), Tongce Medical (+8.1%), and Nuosige (+5.7%), while underperformers include Haoyuan Pharmaceutical (-6.2%) and Baicheng Pharmaceutical (-4.5%) [3][27]. Valuation Metrics - The medical services sector's PE ratio has increased by 0.56X from the previous week, while the PB ratio has risen by 0.06X, indicating a strengthening in market confidence [4][29]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO in the pharmaceutical outsourcing sector, as well as companies like WuXi AppTec and Haoyuan Pharmaceutical [10][64]. - It also recommends monitoring private medical service providers with compliance experience, such as Aier Eye Hospital, as they are expected to benefit from the evolving regulatory landscape [5][64].

Summary of the Conference Call on the Invisible Orthodontics Industry Industry Overview - The conference focused on the **invisible orthodontics industry**, particularly in the context of the Chinese market and the competitive landscape involving key players like **Angelalign**, **Invisalign**, and **Zhengya** [2][3]. Key Points and Arguments Market Growth and Trends - Initial expectations for the invisible orthodontics market in China were optimistic, with anticipated annual growth rates of at least **30%**. However, actual growth over the past two to three years has been slow, ranging from **0% to 10%**, with some years experiencing negative growth [2][3]. - Factors contributing to this slowdown include: - **Macroeconomic conditions** affecting consumer spending [2]. - **Increased competition** and **price reductions** due to collective procurement initiatives [3]. Competitive Landscape - The market is witnessing a **consolidation phase**, with smaller players exiting the market. For instance, a company named **Meilike** ceased operations, transferring its remaining cases to Angelalign and Zhengya, indicating a market cleanup [3]. - The top three companies dominate the market, with their combined market share exceeding **90%**. The ranking is as follows: 1. **Angelalign** 2. **Zhengya** 3. **Invisalign** [4]. Market Share Dynamics - **Invisalign's** market share has been declining, primarily due to competitive pressures and collective procurement initiatives. It was noted that **Invisalign** abandoned a bid during a collective procurement in **October 2022**, resulting in a loss of public hospital market share [4][5]. - Projections for market share in **2025** estimate: - Angelalign: **35%** - Zhengya: **25-30%** - Invisalign: **20%** [5]. Future Growth Projections - The overall market is expected to grow by **5-10%** in the coming years, driven by: - Increased adoption of invisible orthodontics among children and teenagers. - A shift from traditional braces to invisible aligners among adults due to lower prices [6]. - The **2026 collective procurement** is a critical factor that could impact pricing and market dynamics [7]. International Market Insights - Angelalign's international sales are projected to grow significantly, with estimates of **25,000 to 27,000 cases** in **2025**, up from **14,000** in **2024** [8]. - The international market has historically been dominated by **Invisalign**, but Angelalign is gaining traction due to its competitive pricing and service offerings [9][10]. Profitability and Cost Structure - The company's gross margin in China has been declining due to price competition, while margins in international markets are expected to improve as they focus on mid-to-high-end products [13][14]. - The anticipated gross margin in international markets is expected to be higher than in China due to better pricing strategies and product positioning [14]. Legal and Patent Issues - Angelalign is currently facing patent infringement lawsuits from **Invisalign** in multiple regions, including the U.S. and Europe. However, the company denies any infringement and is actively defending itself [15][16]. - Historical data suggests that such lawsuits have a low success rate in preventing market entry for competitors [16]. Additional Important Insights - The conference highlighted the importance of monitoring the **2026 collective procurement** and its potential impact on pricing strategies [7]. - The competitive landscape is shifting, with Angelalign and Zhengya expected to continue gaining market share at the expense of Invisalign [17]. - The overall sentiment is cautiously optimistic, with expectations of gradual recovery and growth in the invisible orthodontics market as economic conditions improve [17].

Core Viewpoint - The report highlights the performance of the China Europe Medical Health Mixed Fund managed by Ge Lan and Zhao Lei, indicating a decline in total fund size and negative returns compared to benchmarks [1][4]. Fund Performance - As of December 31, 2025, the total size of the funds managed by Ge Lan decreased from 43.544 billion to 35.389 billion yuan [1]. - The A-class share of the China Europe Medical Health Mixed Fund recorded a net value growth rate of -14.81%, while the C-class share saw a decline of -14.98%, both underperforming the benchmark return of -8.21% [1][3]. Holdings Overview - The top ten holdings of the China Europe Medical Health Fund include WuXi AppTec, Heng Rui Medicine, and Kanglong Chemical, with notable increases in holdings for Hai Si Ke and Tai Ge Medicine, while reductions were seen in stocks like Ke Lun Pharmaceutical and Xin Li Tai [1][2]. Market Context - In Q4 2025, the CSI Pharmaceutical Index fell by 12.7%, underperforming the CSI 300 Index, which declined by only 0.2%. The report notes significant differentiation within sub-sectors, with innovative industries experiencing corrections while traditional Chinese medicine and pharmaceutical commerce remained relatively stable [3]. Future Outlook - Looking ahead to Q1 2026, improvements in global liquidity are expected to boost investment and financing in innovative pharmaceuticals, supported by domestic policy enhancements. The innovative drug and device industry is anticipated to maintain a high level of activity, with several key domestic drugs approaching critical data readouts [4][5]. - The report suggests that the pharmaceutical sector may continue to experience structural trends due to macroeconomic improvements, supportive industry policies, and ongoing innovation, with investment opportunities focusing on the progress of innovative drug and device exports, domestic substitution in equipment, and recovery in consumer healthcare demand [5].

Core Viewpoint - The report highlights the performance of the China Europe Medical Health Mixed Fund, managed by Ge Lan and Zhao Lei, indicating a decline in total fund size and negative returns compared to benchmarks for the fourth quarter of 2025 [1][4]. Fund Performance - As of December 31, 2025, the total size of funds managed by Ge Lan decreased from 43.544 billion to 35.389 billion yuan [1]. - The net value growth rate for Class A shares of the China Europe Medical Health Mixed Fund was -14.81%, while the benchmark return was -8.21% [1]. - Class C shares experienced a net value growth rate of -14.98%, also underperforming the benchmark [1]. Holdings Overview - The top ten holdings of the China Europe Medical Health Mixed Fund include WuXi AppTec, Heng Rui Medicine, and Kanglong Chemical, with notable increases in holdings for Hai Si Ke and Tai Ge Medicine, while reductions were seen in stocks like Ke Lun Pharmaceutical and Xin Li Tai [1][2]. - The largest holding, WuXi AppTec, accounted for 10.11% of the fund's net value, with a market value of approximately 2.724 billion yuan [2]. Market Context - The CSI Medical Index fell by 12.7% in the fourth quarter of 2025, underperforming the Shanghai and Shenzhen 300 Index, which declined by only 0.2% [3]. - There was significant differentiation within sub-sectors, with the innovative industry chain entering a correction phase after previous gains, while traditional Chinese medicine and pharmaceutical commerce showed relative stability [3]. Future Outlook - Looking ahead to the first quarter of 2026, improvements in global liquidity are expected to boost investment and financing in innovative drugs, supported by domestic policy enhancements [4]. - The innovative drug and medical device industry chain is anticipated to maintain high levels of activity, with several key domestic drugs approaching critical data readout points [5]. - The CXO sector is expected to benefit from a recovery in biotechnology financing, leading to improved order conditions [5]. - The pharmaceutical sector is projected to experience structural trends driven by macroeconomic improvements, supportive industry policies, and ongoing innovation [5].

Core Insights - The 2025 fund's fourth quarterly report reveals that only 5 out of 16 large-cap active equity funds achieved positive returns in Q4, indicating significant performance divergence among funds [1][3][19] - Despite the Q4 challenges, many funds showed a rebound in performance since the beginning of 2026, with 14 out of 16 funds reporting positive returns [3][19] Fund Performance Summary - The top-performing funds in Q4 included: - Guangfa Multi-Factor with a quarterly increase of 3.08% - Dachen Gaoxin A with a return of 1.72% - Fuqun Tianhui Select Growth A with a return of 5.94% [2][3][18] - Conversely, the worst performers included: - Zhongou Medical Health A, which fell by 14.81% - Yifangda Blue Chip Select, which dropped by 8.93% [3][18] Fund Manager Insights - Zhang Kun emphasized the importance of domestic consumption and the long-term potential of investing in domestic demand companies, despite current market skepticism [4][19] - Ge Lan highlighted structural opportunities in the pharmaceutical industry, focusing on innovation and consumer recovery, with a positive outlook for Q1 2026 [6][20] - Liu Yanchun pointed out the need for improved domestic demand and stable asset prices, predicting a rise in inflation expectations [7][21] - Zheng Weishan maintained a focus on hard technology investments, particularly in the semiconductor sector, and expressed optimism about AI demand and domestic production [8][22] - Zhao Yi discussed a dual focus on AI growth and sectors like new energy and military, emphasizing the importance of fundamental analysis [10][25] - Qiao Qian stressed the need for a balance between valuation and fundamentals amid market volatility, aiming for long-term certainty [12][26] - Liu Huiying expressed confidence in the semiconductor and AI applications as key mid-term themes, anticipating breakthroughs in domestic technology [13][27] - Zhao Feng focused on the overseas growth potential of leading companies, noting a shift from product export to local manufacturing and services [14][28] - Xie Zhiyu highlighted the opportunities in the global computing wave and domestic breakthroughs, particularly in the semiconductor sector [15][29] Overall Market Sentiment - Fund managers share a common belief in the long-term potential of the Chinese economy, focusing on industrial upgrades, technological innovation, and the enduring value of quality companies [16][30]

Core Insights - The Chinese healthcare industry has undergone a significant transformation from 2020 to 2025, transitioning from a "golden era" of investment to a "bubble-clearing period" characterized by a K-shaped divergence in market performance [1][2][4]. Group 1: K-shaped Downward Trends - The collapse of previously successful business models, particularly in CXO, consumer healthcare, and internet healthcare, has led to substantial market value losses, with some companies experiencing declines of over 90% [4][7]. - The downturn is attributed to macroeconomic factors such as U.S. interest rate hikes and geopolitical tensions, as well as microeconomic issues like supply-demand imbalances and the disappearance of growth dividends [8][10]. - The CXO sector, once seen as a perpetual growth engine, has faced a 46.68% decline for WuXi Biologics and 44.47% for Tigermed, revealing the fragility of its business model reliant on continuous global financing [12][10]. - Consumer healthcare has suffered a "Davis double whammy," with companies like Yonghe Medical and Aier Eye Hospital seeing declines of 86.19% and 52.69%, respectively, as consumer spending shifts away from discretionary healthcare services [14][15]. - Internet healthcare companies, including Zhiyun Health and Dingdang Health, have also faced severe declines, with drops of 92.44% and 90.67%, as the market realizes that their revenue largely comes from online drug sales rather than innovative healthcare solutions [19][21]. Group 2: K-shaped Upward Trends - In contrast, companies with strong global rights and hard-core technology have thrived, with Keren Biotechnology and Kangfang Biopharma seeing increases of 518.33% and 166.72%, respectively, marking a shift towards biopharma and global market engagement [29][31]. - The rise of these companies signifies a new era where capital is attracted to firms that can demonstrate robust clinical data and global market potential, moving away from mere concepts [30][31]. - Even within struggling sectors, some companies like WuXi AppTec and Yuyue Medical have shown resilience, with increases of 113.36% and 28.75%, respectively, by focusing on high-tech, high-barrier services [34][35]. Group 3: Challenges Ahead - Despite the emergence of new leaders, significant challenges remain, including the risks associated with licensing agreements that may compromise long-term profitability [36][37]. - The ADC sector is experiencing a rush similar to the past PD-1 craze, raising concerns about market saturation and price competition, which could undermine future profitability [39][40]. - The ongoing "ice age" in the primary market poses a threat to innovation, as funding for early-stage companies has become increasingly scarce, potentially leading to a decline in new drug approvals in the coming years [42][43].

Core Insights - The article discusses the growing importance of consumer healthcare products in addressing chronic health issues like obesity, insomnia, hair loss, myopia, and low immunity, emphasizing the need for pharmaceutical companies to align products with consumer demands and establish effective sales channels [1] Group 1: Market Trends and Company Strategies - Pharmaceutical companies are increasingly entering the consumer healthcare sector, with notable examples including Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, which have generated significant revenue [1] - Sanofi's product, Lybrel, is expected to become a star product in the Chinese market by 2025, showcasing the potential for online sales growth [1] - Three Life Pharmaceuticals' Mandi International is set to go public in Hong Kong, with its minoxidil hair loss treatment dominating the Chinese market, projecting revenue growth from 982 million to 1.455 billion yuan from 2022 to 2024, representing a compound annual growth rate of 21.7% [1] Group 2: Product Performance and Market Position - Mandi's hair loss treatment accounted for over 90% of its total revenue from 2022 to mid-2025, highlighting the substantial market for hair loss products in China [1] - Compared to service-oriented companies like Yonghe Medical, Mandi demonstrates superior profitability in the consumer healthcare sector, indicating that product-based companies can achieve higher margins [1] Group 3: Innovations in Consumer Healthcare - Eisai's Lybrel has gained traction due to its novel mechanism of action, which avoids the regulatory constraints of traditional sedative-hypnotics, and its partnership with JD Health enhances its market reach [2][3] - The dual orexin receptor antagonists (DORAs) used in Lybrel promote natural sleep by inhibiting the overactive orexin system, reducing dependency and side effects associated with traditional sleep medications [2] Group 4: Market Opportunities and Challenges - The consumer healthcare market in China has reached a trillion yuan scale, with early entrants gaining brand influence and market share, while new entrants face challenges in competing against established players [5] - There are still unmet needs in various segments such as osteoporosis, sports rehabilitation, and skin care, suggesting opportunities for new products in the consumer healthcare space [6]

Core Insights - The article highlights the growing concern of hair loss among young people in China, with approximately 340 million individuals affected, leading to a burgeoning market for hair health management, projected to reach 52.7 billion yuan by 2024, up from 19.8 billion yuan in 2018 [4][9][12]. Group 1: Market Dynamics - The topic of hair loss has garnered over 2.86 billion views on Xiaohongshu, indicating significant consumer interest and anxiety [4]. - The hair health management market in China is expected to grow to 171.4 billion yuan by 2035, with the hair loss treatment market alone projected to increase from 500 million yuan in 2018 to 3.5 billion yuan in 2024, marking a sevenfold growth over seven years [12][18]. Group 2: Company Overview - Mandi International, a leading player in the hair loss treatment sector, has submitted its IPO application to the Hong Kong Stock Exchange, aiming to become the first public company focused on hair loss prevention [5][6]. - The company has a strong market presence, holding a 71% market share in the minoxidil segment, with a compound annual growth rate (CAGR) of 21.9% in revenue from 2022 to 2024 [18][20]. Group 3: Financial Performance - Mandi International's revenue reached 982 million yuan in 2022, 1.23 billion yuan in 2023, and is projected to be 1.46 billion yuan in 2024, with net profits of 202 million yuan, 341 million yuan, and 390 million yuan respectively during the same period [20]. - The company's gross margin has consistently remained above 80%, while net margins are between 20% and 30%, indicating strong profitability comparable to high-margin industries like liquor [21]. Group 4: Challenges and Risks - Mandi International faces significant risks, including a heavy reliance on its main product line, which accounted for approximately 92% of total revenue from 2022 to mid-2025 [23][24]. - The company has experienced a decline in research and development spending, which fell to 2.62% of revenue in the first half of 2025, down from 8.15% in 2022, raising concerns about its long-term innovation capabilities [25]. - The concentration of suppliers and customers poses additional risks, with the top five suppliers accounting for 75.6% of total purchases and the top five customers contributing 62.6% of revenue [26].

Investment Rating - The report indicates a weak performance in the cosmetics and medical beauty sector, with the Shenwan Beauty Care Index declining by 1.6% from December 5 to December 12, 2025, underperforming the market [3][4]. Core Insights - The cosmetics sector faced pressure in November, with overall GMV in the Taobao system showing weakness due to the pre-promotion of the Double 11 sales event and the rise of Douyin as a sales channel. Brands like Han Shu and Lin Qingxuan maintained stable GMV, while others like Feicui continued to grow significantly [3][9]. - The collagen medical beauty segment is expanding, with two new animal-derived collagen products approved for market entry, expected to drive growth in this area [3][9]. - The report highlights the leading market share of Minoxidil products from Mandi International in the hair loss treatment market, with a steady revenue growth from 982 million yuan in 2022 to approximately 1.455 billion yuan in 2024, reflecting a CAGR of 21.7% from 2022 to 2024 [10][11]. - L'Oréal's acquisition of an additional 10% stake in Galderma, raising its total ownership to 20%, signifies a strategic shift towards the medical beauty and skin health sectors, aiming to adapt to the slowing growth in the Chinese beauty market [3][18]. Summary by Sections Industry Performance - The Shenwan Beauty Care Index and its sub-indices for cosmetics and personal care products have shown declines of 1.2% and 1.7%, respectively, indicating underperformance compared to the Shenwan A Index [4][6]. Key Market Developments - The overall GMV for cosmetics in November was weak, influenced by earlier sales spikes in October and competition from Douyin [9]. - The approval of new collagen products is expected to enhance the supply side of the medical beauty market, with projections for continued expansion in 2026 [9][22]. Company Highlights - Mandi International has maintained a dominant position in the Minoxidil market, with its products accounting for approximately 57% and 71% of the market share in the hair loss treatment and Minoxidil categories, respectively, as of 2024 [11][13]. - The report notes that the Chinese consumer healthcare market is projected to grow from 931.3 billion yuan in 2018 to 16.42 trillion yuan by 2024, with significant growth in hair health and skin health segments [12][13].